9 studies found for:    regorafenib AND GIST | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
regorafenib AND GIST | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: regorafenib
2 Recruiting Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: Sunitinib;   Drug: Regorafenib
3 Recruiting Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Condition: Gastrointestinal Stromal Tumour (GIST)
Intervention: Drug: regorafenib
4 Recruiting A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
Condition: Gastrointestinal Stromal Tumour
Interventions: Drug: Regorafenib;   Drug: imatinib
5 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
6 Recruiting The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
Conditions: Colorectal Neoplasms;   Gastrointestinal Stromal Tumors
Interventions: Drug: Esomeprazole 40mg concomitantly;   Drug: Esomeprazole 40mg before;   Drug: Regorafenib 160mg or 120mg
7 Recruiting PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: PLX9486;   Drug: PLX3397
8 Recruiting SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo
9 Recruiting Stivarga Regulatory Post-Marketing Surveillance Study in Korea
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (Stivarga,BAY73-4506)

Indicates status has not been verified in more than two years